Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Harnessing Neutrophil Survival Mechanisms during Chronic Infection by Pseudomonas aeruginosa: Novel Therapeutic Targets to Dampen Inflammation in Cystic Fibrosis.

Marteyn BS, Burgel PR, Meijer L, Witko-Sarsat V.

Front Cell Infect Microbiol. 2017 Jun 30;7:243. doi: 10.3389/fcimb.2017.00243. eCollection 2017. Review.

2.

ABCB1 as predominant resistance mechanism in cells with acquired SNS-032 resistance.

Löschmann N, Michaelis M, Rothweiler F, Voges Y, Balónová B, Blight BA, Cinatl J Jr.

Oncotarget. 2016 Sep 6;7(36):58051-58064. doi: 10.18632/oncotarget.11160.

3.

Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity.

Chen Z, Wang Z, Pang JC, Yu Y, Bieerkehazhi S, Lu J, Hu T, Zhao Y, Xu X, Zhang H, Yi JS, Liu S, Yang J.

Sci Rep. 2016 Jul 5;6:29090. doi: 10.1038/srep29090.

4.

Reduction of ciliary length through pharmacologic or genetic inhibition of CDK5 attenuates polycystic kidney disease in a model of nephronophthisis.

Husson H, Moreno S, Smith LA, Smith MM, Russo RJ, Pitstick R, Sergeev M, Ledbetter SR, Bukanov NO, Lane M, Zhang K, Billot K, Carlson G, Shah J, Meijer L, Beier DR, Ibraghimov-Beskrovnaya O.

Hum Mol Genet. 2016 Jun 1;25(11):2245-2255. Epub 2016 Apr 5.

5.

Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.

Meijer L, Nelson DJ, Riazanski V, Gabdoulkhakova AG, Hery-Arnaud G, Le Berre R, Loaëc N, Oumata N, Galons H, Nowak E, Gueganton L, Dorothée G, Prochazkova M, Hall B, Kulkarni AB, Gray RD, Rossi AG, Witko-Sarsat V, Norez C, Becq F, Ravel D, Mottier D, Rault G.

J Innate Immun. 2016;8(4):330-49. doi: 10.1159/000444256. Epub 2016 Mar 18.

6.

Bay 61-3606 Sensitizes TRAIL-Induced Apoptosis by Downregulating Mcl-1 in Breast Cancer Cells.

Kim SY, Park SE, Shim SM, Park S, Kim KK, Jeong SY, Choi EK, Hwang JJ, Jin DH, Chung CD, Kim I.

PLoS One. 2015 Dec 31;10(12):e0146073. doi: 10.1371/journal.pone.0146073. eCollection 2015.

7.

Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1.

Lu S, Török HP, Gallmeier E, Kolligs FT, Rizzani A, Arena S, Göke B, Gerbes AL, De Toni EN.

Oncotarget. 2015 Sep 8;6(26):22167-78.

8.

Antitumoral effects of cyclin-dependent kinases inhibitors CR8 and MR4 on chronic myeloid leukemia cell lines.

Troadec S, Blairvacq M, Oumata N, Galons H, Meijer L, Berthou C.

J Biomed Sci. 2015 Jul 17;22:57. doi: 10.1186/s12929-015-0163-x.

9.

Determining the Functions of HIV-1 Tat and a Second Magnesium Ion in the CDK9/Cyclin T1 Complex: A Molecular Dynamics Simulation Study.

Jin HX, Go ML, Yin P, Qiu XT, Zhu P, Yan XJ.

PLoS One. 2015 Apr 24;10(4):e0124673. doi: 10.1371/journal.pone.0124673. eCollection 2015.

10.

Clinical next generation sequencing of pediatric-type malignancies in adult patients identifies novel somatic aberrations.

Silva JG, Corrales-Medina FF, Maher OM, Tannir N, Huh WW, Rytting ME, Subbiah V.

Oncoscience. 2015 Feb 20;2(2):187-92. eCollection 2015.

11.

Selective CDK inhibitors: promising candidates for future clinical traumatic brain injury trials.

Kabadi SV, Faden AI.

Neural Regen Res. 2014 Sep 1;9(17):1578-80. doi: 10.4103/1673-5374.141779. Review.

12.

Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanism.

Norez C, Vandebrouck C, Bertrand J, Noel S, Durieu E, Oumata N, Galons H, Antigny F, Chatelier A, Bois P, Meijer L, Becq F.

Br J Pharmacol. 2014 Nov;171(21):4831-49. doi: 10.1111/bph.12859.

13.

Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis.

Jarry M, Lecointre C, Malleval C, Desrues L, Schouft MT, Lejoncour V, Liger F, Lyvinec G, Joseph B, Loaëc N, Meijer L, Honnorat J, Gandolfo P, Castel H.

Neuro Oncol. 2014 Nov;16(11):1484-98. doi: 10.1093/neuonc/nou102. Epub 2014 Jun 2.

14.

New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.

Ross JS, Wang K, Gay L, Al-Rohil R, Rand JV, Jones DM, Lee HJ, Sheehan CE, Otto GA, Palmer G, Yelensky R, Lipson D, Morosini D, Hawryluk M, Catenacci DV, Miller VA, Churi C, Ali S, Stephens PJ.

Oncologist. 2014 Mar;19(3):235-42. doi: 10.1634/theoncologist.2013-0352. Epub 2014 Feb 21.

15.

Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs.

Löschmann N, Michaelis M, Rothweiler F, Zehner R, Cinatl J, Voges Y, Sharifi M, Riecken K, Meyer J, von Deimling A, Fichtner I, Ghafourian T, Westermann F, Cinatl J Jr.

Transl Oncol. 2013 Dec 1;6(6):685-96. eCollection 2013 Dec 1.

16.

CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.

Delehouzé C, Godl K, Loaëc N, Bruyère C, Desban N, Oumata N, Galons H, Roumeliotis TI, Giannopoulou EG, Grenet J, Twitchell D, Lahti J, Mouchet N, Galibert MD, Garbis SD, Meijer L.

Oncogene. 2014 Dec 11;33(50):5675-87. doi: 10.1038/onc.2013.513. Epub 2013 Dec 9.

17.

Pharmacokinetics and biodistribution of the cyclin-dependent kinase inhibitor -CR8- in mice.

Sallam H, El-Serafi I, Meijer L, Hassan M.

BMC Pharmacol Toxicol. 2013 Sep 30;14:50. doi: 10.1186/2050-6511-14-50.

18.

CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction point.

Bisteau X, Paternot S, Colleoni B, Ecker K, Coulonval K, De Groote P, Declercq W, Hengst L, Roger PP.

PLoS Genet. 2013 May;9(5):e1003546. doi: 10.1371/journal.pgen.1003546. Epub 2013 May 30.

19.

CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD.

Bukanov NO, Moreno SE, Natoli TA, Rogers KA, Smith LA, Ledbetter SR, Oumata N, Galons H, Meijer L, Ibraghimov-Beskrovnaya O.

Cell Cycle. 2012 Nov 1;11(21):4040-6. doi: 10.4161/cc.22375. Epub 2012 Oct 3.

20.

Small-molecule inducers of Aβ-42 peptide production share a common mechanism of action.

Bettayeb K, Oumata N, Zhang Y, Luo W, Bustos V, Galons H, Greengard P, Meijer L, Flajolet M.

FASEB J. 2012 Dec;26(12):5115-23. doi: 10.1096/fj.12-212985. Epub 2012 Sep 12.

Supplemental Content

Support Center